Company cites uncertainty from CMS proposal on 97610 reimbursement rate as reason for withdrawing full-year guidance.
Sanuwave Health withdrew its fiscal 2026 revenue guidance after the Centers for Medicare & Medicaid Services proposed a $316.59 reimbursement rate for code 97610 starting in 2027. The decision reflects concerns over potential revenue impacts from the lower-than-expected rate.
The company reported record applicator sales in Q2 2026, with unit volumes up 13% sequentially from Q1. Despite strong quarterly performance, management opted to remove guidance amid regulatory uncertainty.
No immediate market reaction was disclosed in the earnings call summary.